Tumor News and Research

RSS

Stage III colon cancer patients treated with 5-FU-based chemotherapy after 1995 have improved overall survival

Patients with stage III colon cancer treated with 5-FU-based chemotherapy after complete surgical removal of their tumor after 1995 had improved overall survival with no change in time to recurrence compared to patients treated before 1995. In contrast, patients with stage II colon cancer treated after 1995 had longer time to recurrence and time from recurrence to death compared to those patients treated prior to 1995, according to Mayo Clinic and Gr Hospitalier Pitie-Salpetriere, Paris, researchers.

4 Jun 2010

Functional profiling using EVA/PCD for prescribing treatment regimens for Stage IV NSCLC improve survival

A team of investigators at Rational Therapeutics, Inc. and the Malcolm Todd Cancer Institute (Long Beach, Calif.) has reported that functional profiling using ex-vivo analysis of programmed cell death (EVA/PCD) can be used to prescribe treatment regimens that double the response rate and survival in patients with Stage IV non-small cell lung cancer (NSCLC). The findings of their phase II clinical trial will be presented on Sunday, June 6th at the 46th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago.

4 Jun 2010

Merck launches Oncology Collaborative Trials Network

Today, Merck announced the launch of the Merck Oncology Collaborative Trials Network, a pioneering clinical trial network focusing on the development of Merck drug and vaccine candidates being investigated for the treatment and prevention of cancer. The global network comprises leading cancer research centers who will partner with Merck to speed the development of innovative treatments for a range of cancers.

4 Jun 2010

Anti-seizure drug can be used to treat AT deficiency: Pitt researchers

The liver scarring of α1-antitrypsin deficiency, the most common genetic cause for which children undergo liver transplantation, might be reversed or prevented with a medication that has long been used to treat seizures, according to findings from Children's Hospital of Pittsburgh of UPMC and the University of Pittsburgh School of Medicine that will published in Science and are available online today through the Science Express website.

4 Jun 2010

New therapy mounts double-barreled attack on leukemia, report UF researchers

A new therapy mounts a double-barreled attack on leukemia, targeting not just the cancer cells but also the environment in which those cells live and grow, University of Florida researchers report.

4 Jun 2010

Hiru, MindUp BioResearch comment on recent research findings in cancer treatments

Hiru Corporation and its European subsidiary MindUp BioResearch comment on the recent research findings in the field of cancer treatments for multi-drug resistant non-small cell lung cancer.

4 Jun 2010

Detailed analysis of epigenetics of Wilms tumor reveals similarities to stem cells

A detailed analysis of the epigenetics - factors controlling when and in what tissues genes are expressed - of Wilms tumor reveals striking similarities to stem cells normally found in fetal kidneys. These findings by Massachusetts General Hospital Cancer Center researchers have revealed new cellular pathways that are critical for Wilms tumor development and may also apply to other pediatric cancers.

4 Jun 2010

Early detection and removal of pancreatic cysts may lower cancer risk: Researchers

Working with researchers from the University of Michigan and Indiana University, Van Andel Research Institute investigators have developed a method that could be used to predict whether pancreatic cysts are benign or are precursors to invasive cancer.

4 Jun 2010

Bone-strengthening drug zoledronic acid can help fight breast cancer DTCs: Study

The bone-strengthening drug zoledronic acid (Zometa) can help fight metastatic breast cancer when given before surgery, suggests research at Washington University School of Medicine in St. Louis.

3 Jun 2010

Discovery reveals a new approach to target cancer

Researchers at the University of Pittsburgh Cancer Institute (UPCI) and the School of Medicine have discovered that inhibiting a key molecule in a DNA repair pathway could provide the means to make cancer cells more sensitive to radiation therapy while protecting healthy cells.

3 Jun 2010

Advanced CT scanner allows rapid organ imaging, reduces radiation exposure

UT Southwestern Medical Center is the first site in North Texas to launch the next generation in CT scanners, which allow doctors to image an entire organ in less than a second or track blood flow through the brain or to a tumor - all with less radiation exposure to patients.

3 Jun 2010

Nanosponge delivery system more effective at reducing tumor growth than direct injection: Study

When loaded with an anticancer drug, a delivery system based on a novel material called nanosponge is three to five times more effective at reducing tumor growth than direct injection.

3 Jun 2010

Radiation therapy may not improve chances of survival for bladder cancer patients: Study

In the largest study to date of a rare and deadly form of bladder cancer, researchers at Henry Ford Hospital in Detroit found radiation therapy may not improve a patient's chances for survival.

3 Jun 2010

Case report on clear cell ICC

Intrahepatic cholangiocarcinoma is a cancer of the bile duct in the liver. The clear cell subtype of ICC is a rare cancer; until now, only 8 cases have been reported. The number of reports is so small that a detail description of clear cell ICC is valuable.

3 Jun 2010

ACT Biotech's Telatinib receives orphan drug designation from FDA for treatment of gastric cancer

ACT Biotech Inc., a privately held biotechnology company developing a portfolio of oral kinase inhibitors as anti-cancer drugs, announced today that the company's highly selective oral kinase inhibitor, Telatinib, has received orphan drug designation from the U.S. Food and Drug Administration for the treatment of gastric cancer.

3 Jun 2010

Phase III study of Afinitor tablets in patients with advanced pancreatic NET meets primary endpoint

Novartis Pharmaceuticals Corporation announced today that a Phase III study of Afinitor (everolimus) tablets plus best supportive care met its primary endpoint, showing the drug significantly extended progression-free survival, or time without tumor growth, in patients with advanced pancreatic neuroendocrine tumors.

3 Jun 2010

Researchers discover relationship between DNA methylation and positioning of nucleosomes

A previously unknown pattern in DNA methylation - an event that affects cell function by altering gene expression - has been uncovered for the first time by stem cell researchers at UCLA, a finding that could have implications in preventing some cancers and correcting defects in human stem cell lines.

3 Jun 2010

Ablation technique as affective as conventional surgery for treating kidney cancer

A minimally invasive technique used to destroy kidney tumors with an electrically controlled heating probe showed similar effectiveness as surgical removal of tumors in curbing cancer recurrence rates for up to five years after treatment.

3 Jun 2010

ENMD-2076 demonstrates antitumor activity against murine xenograft models of CRC: Study

EntreMed, Inc., today announced the publication of preclinical results for its clinical-stage Aurora A/angiogenic kinase inhibitor, ENMD-2076, in human colorectal cancer xenograft models. The results of the study, conducted by EntreMed collaborators at the University of Colorado School of Medicine, were published in the June 1, 2010 issue of Clinical Cancer Research (Vol. 16, Issue 11).

2 Jun 2010

Asuragen obtains license to integrate BRAF V600E mutation sequence into its molecular diagnostic products

Asuragen, Inc., a leader in molecular diagnostics and RNA-based pharmacogenomics services, announced today that it has obtained a non-exclusive license to incorporate the BRAF V600E mutation sequence into Asuragen's molecular diagnostic products. The license was obtained from Johns Hopkins University and includes the use of the BRAF V600E mutation as a component of diagnostic test kits and for use in Asuragen's CLIA laboratory for clinical research and patient testing.

2 Jun 2010

Tumor News and Research

Stage III colon cancer patients treated with 5-FU-based chemotherapy after 1995 have improved overall survival

Functional profiling using EVA/PCD for prescribing treatment regimens for Stage IV NSCLC improve survival

Merck launches Oncology Collaborative Trials Network

Anti-seizure drug can be used to treat AT deficiency: Pitt researchers

New therapy mounts double-barreled attack on leukemia, report UF researchers

Hiru, MindUp BioResearch comment on recent research findings in cancer treatments

Detailed analysis of epigenetics of Wilms tumor reveals similarities to stem cells

Early detection and removal of pancreatic cysts may lower cancer risk: Researchers

Bone-strengthening drug zoledronic acid can help fight breast cancer DTCs: Study

Discovery reveals a new approach to target cancer

Advanced CT scanner allows rapid organ imaging, reduces radiation exposure

Nanosponge delivery system more effective at reducing tumor growth than direct injection: Study

Radiation therapy may not improve chances of survival for bladder cancer patients: Study

Case report on clear cell ICC

ACT Biotech's Telatinib receives orphan drug designation from FDA for treatment of gastric cancer

Phase III study of Afinitor tablets in patients with advanced pancreatic NET meets primary endpoint

Researchers discover relationship between DNA methylation and positioning of nucleosomes

Ablation technique as affective as conventional surgery for treating kidney cancer

ENMD-2076 demonstrates antitumor activity against murine xenograft models of CRC: Study

Asuragen obtains license to integrate BRAF V600E mutation sequence into its molecular diagnostic products

Industry Focus eBook - Cell & Gene Therapy (1st Edition) eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News